A new blood test that can detect Alzheimer's disease in mere minutes has the potential to revolutionise treatment.

Researchers have identified a key mechanism in the development of Alzheimer's disease involving the growth and pause of amyloid β fibrils. A newly discovered antibody can lock these fibrils in their ...

New research reveals Alzheimer’s disease may damage the brain in two distinct phases, offering new insights for diagnosis and ...

Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. Researchers at School of Medicine have ...

(NASDAQ: CGTX), a clinical-stage biopharmaceutical company, presented data at the Clinical Trials on Alzheimer's Disease (CTAD ... as a predictive biomarker for treatment effectiveness.

Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play ...

(NASDAQ: CGTX), a clinical-stage biopharmaceutical company, presented data at the Clinical Trials on Alzheimer's Disease (CTAD) conference today ... suggested that plasma p-tau217 could serve as a ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Donanemab, manufactured by pharmaceutical giant Eli Lilly, is a targeted antibody drug which slows down the early stages of ...

AbbVie is set to acquire Aliada Therapeutics for $1.4 billion, targeting an early-stage Alzheimer's treatment. This strategic ...

AbbVie's $1.4 billion acquisition of Aliada Therapeutics is more than a routine buyit's a strategic leap into high-stakes ...

Cure Alzheimer's Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer's disease. Since its founding in 2004, Cure Alzheimer's Fund has ...